Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gareth Pryce

Showing results (1-10 of 65) with videos related to

Pageof 7
Sort By:
Trends in Neurosciences|May 4, 2005
Emerging properties of cannabinoid medicines in management of multiple sclerosisGareth Pryce, David Baker
British Journal of Pharmacology|August 12, 2017
Antidote to cannabinoid intoxication: the CB<sub>1</sub> receptor inverse agonist, AM251, reverses hypothermic effects of the CB<sub>1</sub> receptor agonist, CB-13, in miceGareth Pryce, David Baker
Evidence-Based Medicine|April 22, 2015
Cannabinoids fail to show evidence of slowing down the progression of multiple sclerosisGareth Pryce, David Baker
Current Pharmaceutical Design|September 11, 2008
The endocannabinoid system and multiple sclerosisDavid Baker, Gareth Pryce
Multiple Sclerosis and Related Disorders|August 3, 2018
Oligoclonal bands in multiple sclerosis; Functional significance and therapeutic implications. Does the specificity matter?Gareth Pryce, David Baker
Expert Opinion on Investigational Drugs|April 1, 2003
The therapeutic potential of cannabis in multiple sclerosisDavid Baker, Gareth Pryce
Handbook of Experimental Pharmacology|September 27, 2015
Endocannabinoids in Multiple Sclerosis and Amyotrophic Lateral SclerosisGareth Pryce, David Baker
CNS & Neurological Disorders Drug Targets|May 16, 2012
Potential control of multiple sclerosis by cannabis and the endocannabinoid systemGareth Pryce, David Baker
Neuroscience Letters|April 11, 2003
Mifepristone or inhibition of 11beta-hydroxylase activity potentiates the sedating effects of the cannabinoid receptor-1 agonist Delta(9)-tetrahydrocannabinol in miceGareth Pryce, Gavin Giovannoni, David Baker
Multiple Sclerosis and Related Disorders|February 21, 2019
Potential mechanisms of action related to the efficacy and safety of cladribineDavid Baker, Gareth Pryce, Samuel S Herrod, et al.
Pageof 7

Showing results (1-10 of 65) with videos related to

Sort By:
Pageof 7
Trends in Neurosciences|May 4, 2005
Emerging properties of cannabinoid medicines in management of multiple sclerosisGareth Pryce, David Baker
British Journal of Pharmacology|August 12, 2017
Antidote to cannabinoid intoxication: the CB<sub>1</sub> receptor inverse agonist, AM251, reverses hypothermic effects of the CB<sub>1</sub> receptor agonist, CB-13, in miceGareth Pryce, David Baker
Evidence-Based Medicine|April 22, 2015
Cannabinoids fail to show evidence of slowing down the progression of multiple sclerosisGareth Pryce, David Baker
Current Pharmaceutical Design|September 11, 2008
The endocannabinoid system and multiple sclerosisDavid Baker, Gareth Pryce
Multiple Sclerosis and Related Disorders|August 3, 2018
Oligoclonal bands in multiple sclerosis; Functional significance and therapeutic implications. Does the specificity matter?Gareth Pryce, David Baker
Expert Opinion on Investigational Drugs|April 1, 2003
The therapeutic potential of cannabis in multiple sclerosisDavid Baker, Gareth Pryce
Handbook of Experimental Pharmacology|September 27, 2015
Endocannabinoids in Multiple Sclerosis and Amyotrophic Lateral SclerosisGareth Pryce, David Baker
CNS & Neurological Disorders Drug Targets|May 16, 2012
Potential control of multiple sclerosis by cannabis and the endocannabinoid systemGareth Pryce, David Baker
Neuroscience Letters|April 11, 2003
Mifepristone or inhibition of 11beta-hydroxylase activity potentiates the sedating effects of the cannabinoid receptor-1 agonist Delta(9)-tetrahydrocannabinol in miceGareth Pryce, Gavin Giovannoni, David Baker
Multiple Sclerosis and Related Disorders|February 21, 2019
Potential mechanisms of action related to the efficacy and safety of cladribineDavid Baker, Gareth Pryce, Samuel S Herrod, et al.
Pageof 7